ESMO 2024 Insights: POD1UM-303/InterAACT 2 - Retifanlimab + C-P in Untreated Inoperable or Metastatic Anal Squamous Cell Carcinoma

5 views
September 27, 2024
0 Comments
Login to view comments. Click here to Login